Announced details
Regenerative medicine and gene therapy; GPC-1-positive relapsed/refractory solid cancers
Our development project was selected for an AMED open call program, and we will receive a grant. Capital, personnel, and business relationships are not disclosed.
National Research and Development Agency. Other information, including its location, representative, business activities, capital, and year of establishment, is not disclosed.
There will be no impact on consolidated results for the fiscal year ending March 2027. The final grant amount is expected to be determined in the next fiscal year, and we will promptly announce it once confirmed.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Novel GPC-1 CAR-T therapy for GPC-1-positive relapsed/refractory solid cancers |
| Counterparty | Japan Agency for Medical Research and Development (AMED) |
| Counterparty overview | National Research and Development Agency. Other information, including its location, representative, business activities, capital, and year of establishment, is not disclosed. |
| Relationship with the Company | Our development project was selected for an AMED open call program, and we will receive a grant. Capital, personnel, and business relationships are not disclosed. |
| Launch date | 1 April 2026 (start of the grant-funded project period; stated as the period start date rather than a planned date) |
| Applicable area | Regenerative medicine and gene therapy; GPC-1-positive relapsed/refractory solid cancers |
| Impact on Business Performance | There will be no impact on consolidated results for the fiscal year ending March 2027. The final grant amount is expected to be determined in the next fiscal year, and we will promptly announce it once confirmed. |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The project, for which selection was announced on 10 December 2024, has continued to be selected for FY2026. The final grant amount and the timing of its recognition will be determined in AMED's grant award notification.